摘要
目的 探讨变异型p53蛋白表达对人乳腺癌细胞阿霉素抗药性的影响。方法 应用琼脂培养MTT法检测阿霉素 (ADM)对 9例人乳腺癌新鲜标本药物敏感性。用S -P免疫组化技术观察变异型p53蛋白表达 ,并用ICM - 10 0细胞DNA图像分析系统作半定量分析 ;同时观察阿霉素对人乳腺癌手术前化疗疗效。结果 (1) 9例人乳腺癌新鲜标本中 7例变异型p53蛋白表达阳性 (阳性率为 77.77% )。 (2 )变异型p53蛋白表达量 (阳性面积占总面积百分比 )与人乳腺癌细胞阿霉素抗药指数 (人乳腺癌新鲜标本阿霉素的IC50值与 1/ 10阿霉素血浆峰值浓度的比值 )呈正相关 (r =0 .7956 ,P <0 .0 1)。 (3)变异型p53蛋白表达量与人乳腺癌患者手术前阿霉素化疗疗效积分呈负相关 (r =- 0 .86 37,P <0 .0 1)。
Objective: To investigate the effect of mutant p53 protein expression on resistance of adriamycin to human breast cancer cells. Methods: The MTT assay of agar culture was used to determine chemosensitivity of adriamycin to 9 case of the human breast cancer samples. Expression of mutant p53 protein of human breast cancer cells were proved by Streptavidin-Peroxidase(S-P) immuohistochemical method and the positive reaction were analysed by ICM-100 cell DNA Picture Analysis System. The clinical response with adriamycin for patients with advanced breast cancers before surgical operation were observed simultaneously. Results: (1)Mutant p53 protein expression in 7 cases of the human breast cancer samples were positive, positive rate is 77.77%(7/9). (2)There was positive relationship between expression quantity of mutant p53 protein(positive relative area) and resistance index(IC50/1/10 peak concentration) of adriamyein to human breast cancer cells (r=0.7956, P<0.01). (3)There was negative correlation between expression quantity of mutant p53 protein and the clinical response accumulation value with adriamycin for patients with advanced breast cancer before surgical operation (r=-0.8637, P<0.01). Conclusion: Expression of mutant p53 protien correlate with resistance of adriamycin to human breast cancer cells.
